Home » Stocks » BG Medicine

BG Medicine, Inc. (BGMD)

Stock Price: $0.0208 USD 0.0013 (6.67%)
Updated Aug 13, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 235,445
Revenue (ttm) 1.57M
Net Income (ttm) -5.30M
Shares Out 11.37M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $0.0208
Previous Close $0.0195
Change ($) 0.0013
Change (%) 6.67%
Day's Open 0.0207
Day's Range 0.0200 - 0.0208
Day's Volume 1,320
52-Week Range 0.0071 - 0.0500

More Stats

Market Cap 235,445
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.37M
Float 8.31M
EPS (basic) -0.72
EPS (diluted) -0.72
FCF / Share -0.38
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 630,048
Short Ratio 2.66
Short % of Float 10.14%
Beta 0.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.15
PB Ratio n/a
Revenue 1.57M
Operating Income -4.63M
Net Income -5.30M
Free Cash Flow -3.65M
Net Cash 1.53M
Net Cash / Share 0.13
Gross Margin 67.75%
Operating Margin -295.66%
Profit Margin -444.30%
FCF Margin -233.33%
ROA -75.95%
ROE -902.64%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $0.0208
Target: 5.60
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-43.81%-31.57%44.69%72.28%99.51%-90.35%-41.77%62.32%-
Gross Profit1.061.832.681.861.
Operating Income-4.63-7.36-14.37-22.73-17.49-14.61-15.99-10.58-11.01
Net Income-5.30-8.06-15.85-23.77-17.58-17.16-16.14-15.07-11.39
Shares Outstanding9.618.186.805.054.410.740.730.720.71
Earnings Per Share-0.72-0.99-2.33-4.72-4.00-24.48-23.36-22.08-16.56
Operating Cash Flow-3.67-8.17-15.29-21.33-14.97-11.42-17.98-9.60-3.92
Capital Expenditures0.01--0.03-0.09-0.09-0.08-0.70-0.39-0.74
Free Cash Flow-3.65-8.17-15.32-21.42-15.06-11.49-18.68-9.99-4.66
Cash & Equivalents1.534.127.7513.1824.442.4310.3933.240.00
Total Debt-2.967.319.86-6.371.252.47-
Net Cash / Debt1.531.160.443.3224.44-3.959.1430.770.00
Book Value-1.980.56-1.070.3120.89-77.41-63.90-49.16-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BG Medicine, Inc.
Country United States
Employees 5
CEO Paul R. Sohmer

Stock Information

Ticker Symbol BGMD
Stock Exchange US OTC
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier OTCMKTS: BGMD
IPO Date February 4, 2011


BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.